Becton, Dickinson and Company’s Acquisition of TVA Medical


Fried Frank acted as counsel to Becton, Dickinson and Company

BD, a leading global medical technology company, has completed the acquisition of TVA Medical, Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis.

In the U.S. alone, there are more than 440,000 patients with End-Stage Renal Disease (ESRD) who are surviving on hemodialysisi. The addition of TVA Medical enables BD to offer the everlinQ™ endoAVF System, a new endovascular arteriovenous (AV) fistula creation technology that adds to the company’s ESRD portfolio of dialysis catheters, drug coated balloons, standard angioplasty balloons and endovascular stent graft products. This technology will further improve BD’s ability to serve physicians and their patients by providing a minimally invasive option for creating critical AV fistulas (joining arteries to veins to create a circuit) for hemodialysis procedures.


This transaction is not expected to have a material impact on BD results for fiscal 2018 or 2019. Future results for TVA Medical will be reported under the Peripheral Intervention business within the Interventional Segment at BD. The company used cash on hand to finance the transaction. This transaction does not impact the company’s previously-communicated commitment to deleverage as part of the Bard acquisition. Terms of the transaction were not disclosed.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

The Fried Frank team was led by corporate partner Steven Epstein (Picture) and included executive compensation & ERISA partner Adam Kaminsky; litigation partner Joshua D. Roth; tax partner Michael J. Alter; corporate special counsel Howard A. Fine; corporate associates Christopher S. Celentano, Asad Hussain, and Roy Tannenbaum; environmental associates Samuel K. Dykstra and Mary Beth Phipps; executive compensation & ERISA associate Maggie A. Kornreich; intellectual property and technology associate Marli Sussman; litigation associate Adam Y. Yefet; tax associate Thomas A. Mitchell; and corporate law clerks Mehar Najeeb and Michael G. Riyad.

Involved fees earner: Steven Epstein – Fried Frank Harris Shriver & Jacobson; Howard A. Fine – Fried Frank Harris Shriver & Jacobson; Christopher Celentano – Fried Frank Harris Shriver & Jacobson; Asad Hussain – Fried Frank Harris Shriver & Jacobson; Roy Tannenbaum – Fried Frank Harris Shriver & Jacobson; Adam Kaminsky – Fried Frank Harris Shriver & Jacobson; Maggie Kornreich – Fried Frank Harris Shriver & Jacobson; Joshua D. Roth – Fried Frank Harris Shriver & Jacobson; Adam Yefet – Fried Frank Harris Shriver & Jacobson; Michael Alter – Fried Frank Harris Shriver & Jacobson; Thomas Mitchell – Fried Frank Harris Shriver & Jacobson; Samuel Dykstra – Fried Frank Harris Shriver & Jacobson; Mary Beth Phipps – Fried Frank Harris Shriver & Jacobson; Marli Sussman – Fried Frank Harris Shriver & Jacobson;

Law Firms: Fried Frank Harris Shriver & Jacobson;

Clients: Becton, Dickinson and Company;

Author: Ambrogio Visconti